CRISPR THERAPEUTICS AG — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $864K | ↓-97.6% | — | — | — |
| 2025-09-30 | $889K | ↑+47.7% | $-106M | ↓-23.9% | -14854.8% |
| 2025-06-30 | $892K | ↑+72.5% | $-209M | ↓-65.0% | -25709.0% |
| 2025-03-31 | $865K | ↑+71.6% | $-136M | ↓-16.6% | -17158.8% |
| 2024-12-31 | $36M | ↓-82.3% | — | — | — |
| 2024-09-30 | $602K | — | $-86M | ↑+23.4% | -18294.0% |
| 2024-06-30 | $517K | ↓-99.3% | $-126M | ↓-62.6% | -29257.3% |
| 2024-03-31 | $504K | ↓-99.5% | $-117M | ↓-119.7% | -27894.2% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$864K
↓-97.6% -$35M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
CRSP Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyCRSP Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics